How many drugs treat E. Coli Peritonitis?

Drug Landscape tracks 10 marketed treatments for E. Coli Peritonitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/e-coli-peritonitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

E. Coli Peritonitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

E. Coli Peritonitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating E. Coli Peritonitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Merrem	Meropenem	Pfizer	meropenem		1996-01-01
Zosyn	TAZOBACTAM	Merck Sharp & Dohme B.V.	beta Lactamase Inhibitor		1993-01-01
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Unasyn	SULBACTAM	Pfizer	beta Lactamase Inhibitor	Serine beta-lactamase-like protein LACTB, mitochondrial	1986-01-01
Fortaz	Ceftazidime	Pai Holdings Pharm	Third-generation cephalosporin	Bacterial cell wall	1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Augmentin 250	CLAVULANIC ACID	Dr Reddys Labs Inc	beta Lactamase Inhibitor		1984-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 8 drugs in E. Coli Peritonitis
Pfizer · 3 drugs in E. Coli Peritonitis
Bristol-Myers Squibb · 2 drugs in E. Coli Peritonitis
Pai Holdings Pharm · 2 drugs in E. Coli Peritonitis
Merck Sharp & Dohme B.V. · 1 drug in E. Coli Peritonitis
National Institutes of Health Clinical Center (CC) · 1 drug in E. Coli Peritonitis
Novartis · 1 drug in E. Coli Peritonitis
Sterimax · 1 drug in E. Coli Peritonitis
Tel-Aviv Sourasky Medical Center · 1 drug in E. Coli Peritonitis
University Hospital, Lille · 1 drug in E. Coli Peritonitis
Centre Hospitalier Universitaire Vaudois · 1 drug in E. Coli Peritonitis
Dr Reddys Labs Inc · 1 drug in E. Coli Peritonitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in E. Coli Peritonitis:

Cite this brief

Drug Landscape (2026). E. Coli Peritonitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/e-coli-peritonitis. Accessed 2026-06-11.

E. Coli Peritonitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing